2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Hsieh YL, Jahn A, Menzies NA, Yaesoubi R, Salomon JA, Girma B, Gunde L, Eaton JW, Auld A, Odo M, Kiyiika CN, Kalua T, Chiwandira B, Mpunga JU, Mbendra K, Corbett L, Hosseinipour MC, Cohen T, Kunkel A. Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 85: 643-650. PMID: 33177475, PMCID: PMC8564780, DOI: 10.1097/qai.0000000000002497.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIPT programIPT strategyPreventive therapyContinuous isoniazid preventive therapyMore TB casesHIV-positive adultsCases of tuberculosisAnticipated health effectsComparable health benefitsHIV/AIDSCause deathAntiretroviral therapyTB casesTB controlTB incidenceDrug costsMalawi MinistryMean reductionTuberculosisMycobacterium tuberculosisTherapyAnticipated health impactsHealth effectsHealth benefits
2017
Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies
Wiesch P, Clarelli F, Cohen T. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. PLOS Computational Biology 2017, 13: e1005321. PMID: 28060813, PMCID: PMC5257006, DOI: 10.1371/journal.pcbi.1005321.Peer-Reviewed Original ResearchConceptsOptimal dosingTreatment strategiesOnset of actionAntibiotic treatment strategiesAntibiotic concentrationsOptimal therapyFrequent dosingHigh dosesBacterial infectionsDrug concentrationsDosingBacterial replicationAntibioticsPhysiological fluctuationsAntibiotic effectCellsHIVBacterial growthTherapyCancerInfectionMalariaDoses
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicThe transmission of Mycobacterium tuberculosis in high burden settings
Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, Cobelens FG, Wood R, Moore DA, Abubakar I. The transmission of Mycobacterium tuberculosis in high burden settings. The Lancet Infectious Diseases 2016, 16: 227-238. PMID: 26867464, DOI: 10.1016/s1473-3099(15)00499-5.Peer-Reviewed Original ResearchConceptsHigh-burden settingsBurden settingsTuberculosis infection controlMycobacterium tuberculosis transmissionEffects of HIVHealth care workersDrug-resistant strainsAntiretroviral therapyPerson transmissionTuberculosis transmissionInfection controlTransmission riskAirborne transmissionMycobacterium tuberculosisWells-Riley equationPresent research prioritiesTransmission dynamicsResearch prioritiesHIVEffective strategyTherapyTuberculosisSettingTrials
2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequences
Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions Of The Royal Society B Biological Sciences 2015, 370: 20140306. PMID: 25918446, PMCID: PMC4424438, DOI: 10.1098/rstb.2014.0306.Peer-Reviewed Original ResearchConceptsPreventative therapyDrug resistanceDrug-sensitive pathogensProphylactic antimicrobial therapyLong-term prevalenceSmall pilot studyActive diseaseOverall prevalenceAntimicrobial therapyPrevalencePilot studyTherapyPopulation-level changesPotential population-level effectsDirect effectLevel of coveragePopulation-level effectsHIVTuberculosisMalariaDiseaseCare
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibilityResponse to Comment on “Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis”
Mills HL, Cohen T, Colijn C. Response to Comment on “Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis”. Science Translational Medicine 2013, 5: 204lr4. PMID: 24068734, DOI: 10.1126/scitranslmed.3007442.Peer-Reviewed Original Research
2011
Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLOS ONE 2011, 6: e18327. PMID: 21479171, PMCID: PMC3068161, DOI: 10.1371/journal.pone.0018327.Peer-Reviewed Original ResearchConceptsMultiple drug resistanceDrug resistanceInitial treatment regimensTB control programsAnti-TB drugsDrug-resistant formsEmergence of resistanceFunctional monotherapyTreatment regimensCombination therapyTB strainsTuberculosis treatmentTherapy rangeM. tbTB bacilliMultidrug resistanceM. tuberculosisDifferent antibioticsTherapyTuberculosisInfected hostControl programsResistant formsTBMonotherapy
2010
Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality?
Boulle A, Clayden P, Cohen K, Cohen T, Conradie F, Dong K, Geffen N, Grimwood A, Hurtado R, Kenyon C, Lawn S, Maartens G, Meintjes G, Mendelson M, Murray M, Rangaka M, Sanne I, Spencer D, Taljaard J, Variava E, Venter WD, Wilson D. Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality? South African Medical Journal 2010, 100: 566,568,570-571. PMID: 20822639, DOI: 10.7196/samj.4434.Peer-Reviewed Original Research
2006
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations
Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7042-7047. PMID: 16632605, PMCID: PMC1459015, DOI: 10.1073/pnas.0600349103.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyDrug-resistant TBCommunity-wide isoniazid preventive therapyPreventive therapyTuberculosis infectionTB controlLatent Mycobacterium tuberculosis infectionLatent tuberculosis infectionProportion of patientsMycobacterium tuberculosis infectionIncidence of TBTuberculosis case notificationCommunity-wide implementationEmergence of HIVCommunity-wide strategiesHIV-tuberculosisTB-HIVCoinfected individualsTB epidemicCase notificationTreatment policyHIVTherapyInfectionTB